These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30223116)

  • 1. Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification.
    Darwish SS; Abdel-Halim M; ElHady AK; Salah M; Abadi AH; Becker W; Engel M
    Eur J Med Chem; 2018 Oct; 158():270-285. PubMed ID: 30223116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives.
    Darwish SS; Abdel-Halim M; Salah M; Abadi AH; Becker W; Engel M
    Eur J Med Chem; 2018 Sep; 157():1031-1050. PubMed ID: 30193214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors.
    Schmitt C; Kail D; Mariano M; Empting M; Weber N; Paul T; Hartmann RW; Engel M
    PLoS One; 2014; 9(3):e87851. PubMed ID: 24676346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
    Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
    J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
    Mariano M; Hartmann RW; Engel M
    Eur J Med Chem; 2016 Apr; 112():209-216. PubMed ID: 26896709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.
    Shahroz MM; Sharma HK; Altamimi ASA; Alamri MA; Ali A; Ali A; Alqahtani S; Altharawi A; Alabbas AB; Alossaimi MA; Riadi Y; Firoz A; Afzal O
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35208955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
    Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
    Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Methoxybenzothiophene-2-Carboxamides as Inhibitors of Clk1/4: Optimization of Selectivity and Cellular Potency.
    ElHady AK; El-Gamil DS; Chen PJ; Hwang TL; Abadi AH; Abdel-Halim M; Engel M
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33668683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.
    Rüben K; Wurzlbauer A; Walte A; Sippl W; Bracher F; Becker W
    PLoS One; 2015; 10(7):e0132453. PubMed ID: 26192590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer's disease (AD).
    Gehlot P; Pathak R; Kumar S; Choudhary NK; Vyas VK
    Bioorg Med Chem; 2024 Nov; 113():117925. PubMed ID: 39357433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design.
    Meine R; Becker W; Falke H; Preu L; Loaëc N; Meijer L; Kunick C
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29364148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
    Jarhad DB; Mashelkar KK; Kim HR; Noh M; Jeong LS
    J Med Chem; 2018 Nov; 61(22):9791-9810. PubMed ID: 29985601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a novel chemotype as DYRK1A inhibitors against Alzheimer's disease: Computational modeling and biological evaluation.
    Qiu N; Qian C; Guo T; Wang Y; Jin H; Yao M; Li M; Guo T; Lv Y; Si X; Wu S; Wang H; Zhang X; Xia J
    Int J Biol Macromol; 2024 Jun; 269(Pt 1):132024. PubMed ID: 38704072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel benzothiophene derivatives as potent and narrow spectrum inhibitors of DYRK1A and DYRK1B.
    Segretti ND; Takarada JE; Ferreira MA; da Silva Santiago A; Teodoro BVM; Damião MCFCB; Godoi PH; Cunha MR; Fala AM; Ramos PZ; Ishikawa EE; Mascarello A; Serafim RAM; Azevedo H; Guimarães CRW; Couñago RM
    Bioorg Med Chem Lett; 2022 Jul; 68():128764. PubMed ID: 35504513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
    Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
    Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.
    Allegretti PA; Horton TM; Abdolazimi Y; Moeller HP; Yeh B; Caffet M; Michel G; Smith M; Annes JP
    Bioorg Med Chem; 2020 Jan; 28(1):115193. PubMed ID: 31757680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-step virtual screening to develop selective DYRK1A inhibitors.
    Koyama T; Yamaotsu N; Nakagome I; Ozawa SI; Yoshida T; Hayakawa D; Hirono S
    J Mol Graph Model; 2017 Mar; 72():229-239. PubMed ID: 28129593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins.
    ElHady AK; Abdel-Halim M; Abadi AH; Engel M
    J Med Chem; 2017 Jul; 60(13):5377-5391. PubMed ID: 28561591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of selective dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and their effects on tau and microtubule.
    Wu YW; HuangFu WC; Lin TE; Peng CH; Tu HJ; Sung TY; Sung TY; Yen SC; Pan SL; Hsu KC
    Int J Biol Macromol; 2024 Feb; 259(Pt 1):129074. PubMed ID: 38163507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.